Literature DB >> 8248656

The role of p-values in analysing trial results.

P R Freeman.   

Abstract

The current widespread practice of using p-values as the main means of assessing and reporting the results of clinical trials cannot be defended. Reasons for grave concern over the present situation range from the unsatisfactory nature of p-values themselves, their very common misunderstanding by statisticians as well as by clinicians and their serious distorting influence on our perception of the very nature of clinical trials. It is argued, however, that only by fully understanding the reasons why they have become so universally popular can we hope to change opinion and introduce more sensible ways of summarizing and reporting results. Some of the ways in which this might happen are discussed.

Mesh:

Year:  1993        PMID: 8248656     DOI: 10.1002/sim.4780121510

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  Likelihood ratio meta-analysis: New motivation and approach for an old method.

Authors:  Colin R Dormuth; Kristian B Filion; Robert W Platt
Journal:  Contemp Clin Trials       Date:  2016-02-04       Impact factor: 2.226

2.  Buying a significant result: Do we need to reconsider the role of the P value?

Authors:  Michael R Jiroutek; J Rick Turner
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-26       Impact factor: 3.738

3.  Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism.

Authors:  Sylvia M Dobbs; R John Dobbs; Clive Weller; André Charlett; Ingvar T Bjarnason; Andrew J Lawson; Darren Letley; Lucy Harbin; Ashley B Price; Mohammad A A Ibrahim; Norman L Oxlade; James Bowthorpe; Daniel Leckstroem; Cori Smee; J Malcolm Plant; Dale W Peterson
Journal:  Helicobacter       Date:  2010-08       Impact factor: 5.753

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.